In the prospective randomized phase 2 WJOG8515L trial, patients with advanced EGFR-mutated NSCLC who acquired resistance to EGFR-TKIs without T790M mutation were randomized to receive either nivolumab or carboplatin-pemetrexed. Here, EGFR is linked to non-small cell lung carcinoma.